The natural history of recurrent optic neuritis

Istvan Pirko, Lori K. Blauwet, Timothy G. Lesnick, Brian G Weinshenker

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space. Objective: To define the clinical course and prognosis of patients with recurrent ON. Design: Retrospective medical record review and telephone follow-up survey. Setting: Clinic-based practice in a large tertiary referral institution. Main Outcome Measures: Survival analysis of conversion to MS and NMO and final visual impairment. We studied the association of clinical and demographic factors, the presence of brain lesions on magnetic resonance images, and the use of corticosteroid treatment at the time of the first ON occurrence with conversion to MS and NMO. Results: We identified 1274 patients with ON between 1994 and 2000 and selected 72 (5.7%) with recurrent ON without intervening symptoms of a disseminated demyelinating condition for further analysis. The 5-year conversion rate to NMO was 12.5% and to MS, 14.4%. Among 5 patients with 2 or more lesions consistent with MS on brain magnetic resonance images, 2 (40.0%) converted to MS and none to NMO, while among 11 patients without such lesions, none converted to MS and 2 (18.2%) converted to NMO (P = .16). Conversion to MS occurred in 7 (19.4%) of 36 individuals treated for their first ON episode with corticosteroids vs 4 (44.4%) of 9 untreated individuals (P = .19). There was no difference in the conversion rate to MS between those treated with intravenous steroids (4 [16.7%] of 24) vs oral steroids (3 [25.0%] of 12) (P = .33). Conversion to NMO occurred earlier than conversion to MS (2.3 ± 1.6 vs 5.3 ± 4.3 years, respectively; P = .01). Women tended to convert to NMO more frequently than men (female-male ratio for NMO converters, 7:1; MS converters, 2:1; nonconverters, 2:1; P = .56), as did those with a higher annual frequency of ON episodes (NMO converters, 2.0 ± 1.3; MS converters, 1.0 ± 1.0; nonconverters, 0.6 ± 0.5; P = .04). The number of ON events in the first 2 years following the first ON episode was higher in the NMO group (NMO converters, 2.4 ± 0.9; MS converters, 1.9 ± 1.1; nonconverters, 1.7 ± 0.7; P = .04). The final visual impairment was greatest in the NMO group (P = .02). Conclusions: Patients with rapid succession of severe ON events are more likely to develop a generalized demyelinating disease. Patients with NMO had a worse visual outcome.

Original languageEnglish (US)
Pages (from-to)1401-1405
Number of pages5
JournalArchives of Neurology
Volume61
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Neuromyelitis Optica
Optic Neuritis
Multiple Sclerosis
Vision Disorders
Optics
Adrenal Cortex Hormones
Magnetic Resonance Spectroscopy
Steroids
Brain
Demyelinating Diseases
Survival Analysis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The natural history of recurrent optic neuritis. / Pirko, Istvan; Blauwet, Lori K.; Lesnick, Timothy G.; Weinshenker, Brian G.

In: Archives of Neurology, Vol. 61, No. 9, 09.2004, p. 1401-1405.

Research output: Contribution to journalArticle

Pirko, Istvan ; Blauwet, Lori K. ; Lesnick, Timothy G. ; Weinshenker, Brian G. / The natural history of recurrent optic neuritis. In: Archives of Neurology. 2004 ; Vol. 61, No. 9. pp. 1401-1405.
@article{1c25018816114936b49d3b2339255940,
title = "The natural history of recurrent optic neuritis",
abstract = "Background: Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space. Objective: To define the clinical course and prognosis of patients with recurrent ON. Design: Retrospective medical record review and telephone follow-up survey. Setting: Clinic-based practice in a large tertiary referral institution. Main Outcome Measures: Survival analysis of conversion to MS and NMO and final visual impairment. We studied the association of clinical and demographic factors, the presence of brain lesions on magnetic resonance images, and the use of corticosteroid treatment at the time of the first ON occurrence with conversion to MS and NMO. Results: We identified 1274 patients with ON between 1994 and 2000 and selected 72 (5.7{\%}) with recurrent ON without intervening symptoms of a disseminated demyelinating condition for further analysis. The 5-year conversion rate to NMO was 12.5{\%} and to MS, 14.4{\%}. Among 5 patients with 2 or more lesions consistent with MS on brain magnetic resonance images, 2 (40.0{\%}) converted to MS and none to NMO, while among 11 patients without such lesions, none converted to MS and 2 (18.2{\%}) converted to NMO (P = .16). Conversion to MS occurred in 7 (19.4{\%}) of 36 individuals treated for their first ON episode with corticosteroids vs 4 (44.4{\%}) of 9 untreated individuals (P = .19). There was no difference in the conversion rate to MS between those treated with intravenous steroids (4 [16.7{\%}] of 24) vs oral steroids (3 [25.0{\%}] of 12) (P = .33). Conversion to NMO occurred earlier than conversion to MS (2.3 ± 1.6 vs 5.3 ± 4.3 years, respectively; P = .01). Women tended to convert to NMO more frequently than men (female-male ratio for NMO converters, 7:1; MS converters, 2:1; nonconverters, 2:1; P = .56), as did those with a higher annual frequency of ON episodes (NMO converters, 2.0 ± 1.3; MS converters, 1.0 ± 1.0; nonconverters, 0.6 ± 0.5; P = .04). The number of ON events in the first 2 years following the first ON episode was higher in the NMO group (NMO converters, 2.4 ± 0.9; MS converters, 1.9 ± 1.1; nonconverters, 1.7 ± 0.7; P = .04). The final visual impairment was greatest in the NMO group (P = .02). Conclusions: Patients with rapid succession of severe ON events are more likely to develop a generalized demyelinating disease. Patients with NMO had a worse visual outcome.",
author = "Istvan Pirko and Blauwet, {Lori K.} and Lesnick, {Timothy G.} and Weinshenker, {Brian G}",
year = "2004",
month = "9",
doi = "10.1001/archneur.61.9.1401",
language = "English (US)",
volume = "61",
pages = "1401--1405",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - The natural history of recurrent optic neuritis

AU - Pirko, Istvan

AU - Blauwet, Lori K.

AU - Lesnick, Timothy G.

AU - Weinshenker, Brian G

PY - 2004/9

Y1 - 2004/9

N2 - Background: Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space. Objective: To define the clinical course and prognosis of patients with recurrent ON. Design: Retrospective medical record review and telephone follow-up survey. Setting: Clinic-based practice in a large tertiary referral institution. Main Outcome Measures: Survival analysis of conversion to MS and NMO and final visual impairment. We studied the association of clinical and demographic factors, the presence of brain lesions on magnetic resonance images, and the use of corticosteroid treatment at the time of the first ON occurrence with conversion to MS and NMO. Results: We identified 1274 patients with ON between 1994 and 2000 and selected 72 (5.7%) with recurrent ON without intervening symptoms of a disseminated demyelinating condition for further analysis. The 5-year conversion rate to NMO was 12.5% and to MS, 14.4%. Among 5 patients with 2 or more lesions consistent with MS on brain magnetic resonance images, 2 (40.0%) converted to MS and none to NMO, while among 11 patients without such lesions, none converted to MS and 2 (18.2%) converted to NMO (P = .16). Conversion to MS occurred in 7 (19.4%) of 36 individuals treated for their first ON episode with corticosteroids vs 4 (44.4%) of 9 untreated individuals (P = .19). There was no difference in the conversion rate to MS between those treated with intravenous steroids (4 [16.7%] of 24) vs oral steroids (3 [25.0%] of 12) (P = .33). Conversion to NMO occurred earlier than conversion to MS (2.3 ± 1.6 vs 5.3 ± 4.3 years, respectively; P = .01). Women tended to convert to NMO more frequently than men (female-male ratio for NMO converters, 7:1; MS converters, 2:1; nonconverters, 2:1; P = .56), as did those with a higher annual frequency of ON episodes (NMO converters, 2.0 ± 1.3; MS converters, 1.0 ± 1.0; nonconverters, 0.6 ± 0.5; P = .04). The number of ON events in the first 2 years following the first ON episode was higher in the NMO group (NMO converters, 2.4 ± 0.9; MS converters, 1.9 ± 1.1; nonconverters, 1.7 ± 0.7; P = .04). The final visual impairment was greatest in the NMO group (P = .02). Conclusions: Patients with rapid succession of severe ON events are more likely to develop a generalized demyelinating disease. Patients with NMO had a worse visual outcome.

AB - Background: Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space. Objective: To define the clinical course and prognosis of patients with recurrent ON. Design: Retrospective medical record review and telephone follow-up survey. Setting: Clinic-based practice in a large tertiary referral institution. Main Outcome Measures: Survival analysis of conversion to MS and NMO and final visual impairment. We studied the association of clinical and demographic factors, the presence of brain lesions on magnetic resonance images, and the use of corticosteroid treatment at the time of the first ON occurrence with conversion to MS and NMO. Results: We identified 1274 patients with ON between 1994 and 2000 and selected 72 (5.7%) with recurrent ON without intervening symptoms of a disseminated demyelinating condition for further analysis. The 5-year conversion rate to NMO was 12.5% and to MS, 14.4%. Among 5 patients with 2 or more lesions consistent with MS on brain magnetic resonance images, 2 (40.0%) converted to MS and none to NMO, while among 11 patients without such lesions, none converted to MS and 2 (18.2%) converted to NMO (P = .16). Conversion to MS occurred in 7 (19.4%) of 36 individuals treated for their first ON episode with corticosteroids vs 4 (44.4%) of 9 untreated individuals (P = .19). There was no difference in the conversion rate to MS between those treated with intravenous steroids (4 [16.7%] of 24) vs oral steroids (3 [25.0%] of 12) (P = .33). Conversion to NMO occurred earlier than conversion to MS (2.3 ± 1.6 vs 5.3 ± 4.3 years, respectively; P = .01). Women tended to convert to NMO more frequently than men (female-male ratio for NMO converters, 7:1; MS converters, 2:1; nonconverters, 2:1; P = .56), as did those with a higher annual frequency of ON episodes (NMO converters, 2.0 ± 1.3; MS converters, 1.0 ± 1.0; nonconverters, 0.6 ± 0.5; P = .04). The number of ON events in the first 2 years following the first ON episode was higher in the NMO group (NMO converters, 2.4 ± 0.9; MS converters, 1.9 ± 1.1; nonconverters, 1.7 ± 0.7; P = .04). The final visual impairment was greatest in the NMO group (P = .02). Conclusions: Patients with rapid succession of severe ON events are more likely to develop a generalized demyelinating disease. Patients with NMO had a worse visual outcome.

UR - http://www.scopus.com/inward/record.url?scp=4444347473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444347473&partnerID=8YFLogxK

U2 - 10.1001/archneur.61.9.1401

DO - 10.1001/archneur.61.9.1401

M3 - Article

C2 - 15364686

AN - SCOPUS:4444347473

VL - 61

SP - 1401

EP - 1405

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -